291 related articles for article (PubMed ID: 26997214)
21. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
Pallayova M; Taheri S
Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
[TBL] [Abstract][Full Text] [Related]
22. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
Williams T
FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
[TBL] [Abstract][Full Text] [Related]
23. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
Musso G
Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
[No Abstract] [Full Text] [Related]
24. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B; Staels B
Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
[TBL] [Abstract][Full Text] [Related]
25. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
Ray K
Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
[No Abstract] [Full Text] [Related]
26. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management.
Gracious BL; Bhatt R; Potter C
J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):602-10. PubMed ID: 26447642
[TBL] [Abstract][Full Text] [Related]
27. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Guaraldi G; Maurice JB; Marzolini C; Monteith K; Milic J; Tsochatzis E; Bhagani S; Morse CG; Price JC; Ingiliz P; Lemoine M; Sebastiani G;
Hepatology; 2020 May; 71(5):1831-1844. PubMed ID: 32052857
[TBL] [Abstract][Full Text] [Related]
28. [New pharmacological treatment options for nonalcoholic fatty liver disease].
Stefan N
Internist (Berl); 2020 Jul; 61(7):759-765. PubMed ID: 32409850
[TBL] [Abstract][Full Text] [Related]
29. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Sanyal AJ
Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
[TBL] [Abstract][Full Text] [Related]
30. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
31. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.
Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Sargent R; Hawkins C; Sourianarayanane A; Khiyami A; Yerian L; Pai R; McCullough AJ; Dasarathy S
Liver Int; 2015 Mar; 35(3):979-85. PubMed ID: 24905085
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.
Francque S; Vonghia L
Adv Ther; 2019 May; 36(5):1052-1074. PubMed ID: 30888594
[TBL] [Abstract][Full Text] [Related]
33. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
[No Abstract] [Full Text] [Related]
34. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
35. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Hameed B; Terrault N
Clin Liver Dis; 2016 May; 20(2):365-85. PubMed ID: 27063275
[TBL] [Abstract][Full Text] [Related]
36. Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy.
Tomeno W; Kawashima K; Yoneda M; Saito S; Ogawa Y; Honda Y; Kessoku T; Imajo K; Mawatari H; Fujita K; Saito S; Hirayasu Y; Nakajima A
J Gastroenterol Hepatol; 2015 Jun; 30(6):1009-14. PubMed ID: 25619308
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic Fatty Liver Disease and Liver Transplantation.
Pham T; Dick TB; Charlton MR
Clin Liver Dis; 2016 May; 20(2):403-17. PubMed ID: 27063277
[TBL] [Abstract][Full Text] [Related]
38. The role of medications for the management of patients with NAFLD.
Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease and lipids.
Wierzbicki AS; Oben J
Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
[TBL] [Abstract][Full Text] [Related]
40. Management and diagnosis of fatty liver disease.
Schneier AT; Citti CC; Dieterich DT
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
